Antibody Response to DT–GM, a Novel Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT) Linked to Human Granulocyte–Macrophage Colony Stimulating Factor (GM), during a Phase I Trial of Patients with Relapsed or Refractory Acute Myeloid Leukemia
- 1 August 2001
- journal article
- clinical trial
- Published by Elsevier in Clinical Immunology
- Vol. 100 (2) , 191-197
- https://doi.org/10.1006/clim.2001.5066
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell LymphomaJournal of Clinical Oncology, 2001
- Toxicology and Pharmacokinetics of DTGM, a Fusion Toxin Consisting of a Truncated Diphtheria Toxin (DT388) Linked to Human Granulocyte-Macrophage Colony-Stimulating Factor, in Cynomolgus MonkeysToxicology and Applied Pharmacology, 1999
- DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte–macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemiaLeukemia, 1999
- Long-term survival in acute myeloid leukemiaCancer, 1997
- Long-term survival after chemotherapy for acute myeloid leukemiaCancer, 1997
- Immunotoxins: An UpdateAnnual Review of Immunology, 1996
- Isolation and Characterization of Human Antioxidized LDL AutoantibodiesArteriosclerosis, Thrombosis, and Vascular Biology, 1996
- Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptorBlood, 1992
- Quantitation of anti‐tetanus and anti‐diphtheria antibodies by enzymoimmunoassay: Methodology and applicationsJournal of Clinical Laboratory Analysis, 1991
- HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3Blood, 1988